-
-
FDA accepts first AI algorithm to drug development tool pilot, with Deliberate AI’s anxiety and depression assessment
-
Google captures FDA de novo clearance for Pixel smartphone thermometer app
Neuralink fined for violating hazardous material transport rules, docs show: Reuters
Element Science’s slim cardioverter defibrillator patch claims European approval
Week of IPO success stories suggest biotech has reached ‘recovery phase’ in 2024
In The News
- Economic Storm Clouds Hovering Over Trump and Global Leaders August 25, 2019 By News Team
- UN: Possible to Eradicate Malaria, but Probably Not Soon August 24, 2019 By News Team
- Climate Change Turns Arctic Into Strategic, Economic Hotspot August 23, 2019 By News Team
Biotechnology Daily
more-
FDA accepts first AI algorithm to drug development tool pilot, with Deliberate AI’s anxiety and depression assessment
For the first time since it launched in 2020 and began accepting submissions in 2022,…
Google captures FDA de novo clearance for Pixel smartphone thermometer app
Neuralink fined for violating hazardous material transport rules, docs show: Reuters
Element Science’s slim cardioverter defibrillator patch claims European approval
Silo Pharma’s ketamine-based drug for Alzheimer’s effective against dementia symptoms in mice
Market Watch
more-
Weekly Market Review – May 4, 2024
Stock Markets Major indexes have all registered gains for the week as they continue their…
Asian Markets Follow Wall Street Swings After Fed Keeps Interest Rates High
Federal Reserve Says Interest Rates Will Stay at Two-Decade High Until Inflation Further Cools
US Job Openings Fall to 8.5 Million in March, the Lowest Level in More Than 3 Years
DoorDash Posts Better-Than-Expected Q1 Sales but Shares Fall on Cost Concerns
Bio Business News
moreWeek of IPO success stories suggest biotech has reached ‘recovery phase’ in 2024
Coming off one of the worst periods for IPOs in…
Formosa, fresh from Eyenovia deal, sells Brazilian rights to near-approval eye drug
Formosa Pharmaceuticals has handed over another set of regional rights…
Minoryx, clutching data from failed trial, knocked back by EMA but vows to seek rerun of review
The European Medicines Agency (EMA) has swatted away Minoryx Therapeutics’…
World News
moreStocks close with a round of records, Dow clinches 35,000
U.S. stocks swept to another round of records Monday as…
Equifax stock surges toward biggest gain in 12 years after ‘impressive’ business update
Shares of Equifax Inc. EFX, +7.84% shot up 9.3% into…
SpaceX Starlink wins permit to send internet to customers like you
SpaceX has been busy building its Starlink satellite constellation. To…
- Weekly Market Review – May 4, 2024
- FDA accepts first AI algorithm to drug development tool pilot, with Deliberate AI’s anxiety and depression assessment
- Google captures FDA de novo clearance for Pixel smartphone thermometer app
- Neuralink fined for violating hazardous material transport rules, docs show: Reuters
- Element Science’s slim cardioverter defibrillator patch claims European approval
- Week of IPO success stories suggest biotech has reached ‘recovery phase’ in 2024
- Formosa, fresh from Eyenovia deal, sells Brazilian rights to near-approval eye drug
- Minoryx, clutching data from failed trial, knocked back by EMA but vows to seek rerun of review
- ArriVent takes in $175M from second biotech IPO of the year
- Asian Markets Follow Wall Street Swings After Fed Keeps Interest Rates High